The Top 5 Biosimilars Articles for the Week of June 24
The Center for Biosimilars® recaps the top stories for the week of June 24, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 24.
Number 5: Alexion says that the FDA will give priority review to its long-acting C5 complement inhibitor. The drug offers less frequent administration than Soliris, which faces upcoming biosimilar competition.
Number 4: A UK court has denied Pfizer an Arrow declaration in its pursuit to launch biosimilar bevacizumab.
Number 3: At the ACI 10th Summit on Biosimilars, experts explained the circumstances under which biosimilar developers might challenge patents via the International Trade Commission.
Number 2: Henlius says that the European Medicines Agency will review the company’s trastuzumab biosimilar.
Number 1: Drug maker AbbVie announced that it has reached a transaction agreement under which it will acquire Allergan.
Finally, last week, our e-newsletter asked whether you think the United States is catching up with the European Union in its effort to bring biosimilars to patients.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
